Preoperative gastric cancer immune prognostic score (GCIPS) as a novel biomarker for predicting survival in gastric cancer patients after radical resection: A retrospective cohort study.

This study aimed to validate the preoperative gastric cancer immune prognostic score (GCIPS) as a prognostic biomarker in resectable gastric cancer (GC). We retrospectively analyzed 226 GC patients undergoing radical resection. The optimal cutoff value of the GCIPS was determined by receiver operating characteristic curve analysis, and patients were stratified accordingly to assess its prognostic value for recurrence-free survival and overall survival. The GCIPS was calculated using preoperative blood parameters. Using receiver operating characteristic-derived cutoff (2.840), patients were stratified into high- and low-GCIPS groups. The high-GCIPS group showed significantly poorer tumor differentiation (P < .001). Kaplan-Meier analysis revealed that high GCIPS was associated with worse 5-year recurrence-free survival (hazard ratio = 2.856, P < .001) and overall survival (hazard ratio = 3.222, P < .001). Multivariate analysis confirmed GCIPS as an independent predictor for both outcomes after adjusting for tumor-node-metastasis stage and differentiation. The GCIPS is a robust, independent prognostic biomarker derived from routine blood tests, offering a practical tool for risk stratification and guiding individualized management in GC after radical resection.